Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Cellares

Cellares Appoints Ossama Eissa, Former Novartis, Lonza and Legend Biopharma Leader, as Chief Operating Officer
From Cellares
Via Business Wire
Cellares and Sony Announce a Joint Development Collaboration to Integrate Flow Cytometry-Based Sorting and Online Analysis into an Automated, High-Throughput Cell Therapy Manufacturing Platform
From Cellares
Via Business Wire
Cellares Announces Completion of First cGMP Cell Shuttle at IDMO Smart Factory in Bridgewater, New Jersey
From Cellares
Via Business Wire
Cellares Appoints Justin McAnear as CFO and Jonathan Butler as General Counsel
From Cellares
Via Business Wire
Cellares Announces Agreement with Kite to Evaluate Its Cell Shuttle Automated Manufacturing Platform
From Cellares
Via Business Wire
Cellares Launches Cell Q, the World’s First Automated cGMP QC Workcell for Cell Therapies, to Resolve Manual QC Processing Bottleneck and Extend IDMO Capabilities from Manufacturing Through Quality Control
From Cellares
Via Business Wire
Christi Shaw, Former CEO of Kite, a Gilead Company, Appointed to Cellares Advisory Board to Advance Cell Therapy Manufacturing
From Cellares
Via Business Wire
Cellares Unveils First cGMP Compliant Cell Shuttle in its South San Francisco Center of Excellence
From Cellares
Via Business Wire
Somerset County Welcomes Cellares’ $255M Investment Expected to Create 350 Local Jobs
From Cellares
Via Business Wire
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform
From Cellares
Via Business Wire
Tickers CABA
Cellares Announces Expanded Agreement with Bristol Myers Squibb to Include Second CAR-T Program in Cellares’ Technology Adoption Partnership Program
From Cellares
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.